Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (104)	8/30/2001 9:53:44 PM
From: tuck	Read Replies (1) \| Respond to of 897

Considering the rough road for blood substitutes, throwing a reverse split into the mix should make ALLP a plausible short candidate when it happens. I can't think of any biotech that has done this and not cratered. NEXL comes to mind. I hate to short the locals, but . . . >>SAN DIEGO--(BW HealthWire)--Aug. 30, 2001--Alliance Pharmaceutical Corp. (Nasdaq:ALLP - news) announced today that it has reached an agreement in principle on terms for the private placement of at least $15 million of common shares to a group of institutional investors. The company will seek shareholder approval for the financing, which includes a reverse stock split, at its annual shareholder meeting to be held on October 15, 2001. The securities sold in the contemplated private placement will not be registered under the Securities Act of 1933 and may not be offered or sold in the U.S. absent registration or an applicable exemption from the registration statement requirements of the Act. This financing will be used for working capital and to obtain approval for Imavist(TM), an ultrasound contrast agent being developed with Schering AG, Germany, and to resume the clinical development of Oxygent(TM), an intravascular oxygen carrier being developed by Alliance in the United States, Canada and Europe in conjunction with Baxter Healthcare Corp. << snip Anyone have thoughts on this idea? Cheers, Tuck

To: RCMac who wrote (104)	11/15/2001 4:37:36 PM
From: RCMac	Read Replies (1) \| Respond to of 897

SEC slaps DISE (ex-UBUY) scam anthrax claims: rd.yahoo.com*http://www.marketwatch.com/news/yhoo/story.asp?source=blq/yhoo&siteid=yhoo&dist=yhoo&guid=%7B5449F57B%2D82FF%2D4890%2DAFCF%2DCF266DA4B082%7D >> SEC slaps three false anthrax claims Companies said products targeted toxic bacteria By Leticia Williams, CBS.MarketWatch.com Last Update: 3:34 PM ET Nov. 15, 2001 WASHINGTON (CBS.MW) -- The Securities and Exchange Commission issued cease-and-desist orders against three publicly traded companies that issued press releases after the Sept. 11 attacks, claiming to offer certain products capable of killing or detecting anthrax. In an example of the agency's proclaimed commitment to provide speedier enforcement action, SEC officials said Thursday that the fraudulent claims were brought to the attention of its enforcement division within a few weeks following the terror tragedy. "Today's action enforcement actions make clear that the Commission will act in 'real-time' to sanction such conduct," Stephen Cutler, director of the agency's enforcement division, said in a prepared statement. Each company agreed to the order without admitting or denying the commission's findings. The SEC alleges that two of the companies, Disease Sciences (DISE: news, chart, profile), of Boca Raton, Fla., and The Classica Group (TCGI: news, chart, profile), of Lakewood, N.J., claimed to have developed products capable of killing anthrax. The SEC alleged that a third company, R-Tec Technologies (RTTC: news, chart, profile), of Flanders, N.J., had falsely claimed that it devised a mechanism to detect biological and chemical terrorism, according to an SEC statement Thursday. "I think the commission's response was prompt and effective against these companies that used public anxiety as a springboard for self-promotion," Barry Rashkover, an enforcement official for the SEC's New York division, told reporters Thursday. Phone calls made to each of the companies' lawyers were not immediately returned. Leticia Williams is a reporter for CBS.MarketWatch.com in Washington. <<